2-(2,3-dicarboxycyclopropyl)glycine and Parkinsonian Disorders

2-(2,3-dicarboxycyclopropyl)glycine has been researched along with Parkinsonian Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Machado, A; Mauriño, R; Santiago, M; Venero, JL	1

Other Studies

1 other study(ies) available for 2-(2,3-dicarboxycyclopropyl)glycine and Parkinsonian Disorders

Article	Year
Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals. Neurochemistry international, 2010, Volume: 57, Issue:8 Topics: Animals; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glycine; Male; Neuroprotective Agents; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Wistar	2010

Article

Year

Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals.

Neurochemistry international, 2010, Volume: 57, Issue:8

Topics: Animals; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glycine; Male; Neuroprotective Agents; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Wistar

2010